IL127423A - A medicinal preparation for giving and penetrating mucous membranes in the nose, mouth and throat - Google Patents

A medicinal preparation for giving and penetrating mucous membranes in the nose, mouth and throat

Info

Publication number: IL127423A
Authority: IL; Israel
Prior art keywords: pharmaceutical formulation; liquid pharmaceutical; formulation according; active substance; administration
Prior art date: 1998-01-15

Application number

IL12742398A

Other languages

English (en)

Hebrew (he)

Other versions

IL127423A0 (en

Original Assignee

Immunotech Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-15

Filing date

1998-12-07

Publication date

2004-06-20

1998-12-07 Application filed by Immunotech Sa filed Critical Immunotech Sa

1999-10-28 Publication of IL127423A0 publication Critical patent/IL127423A0/xx

2004-06-20 Publication of IL127423A publication Critical patent/IL127423A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 32
230000035515 penetration Effects 0.000 title description 2
239000013543 active substance Substances 0.000 claims abstract description 60
229960003511 macrogol Drugs 0.000 claims abstract description 24
239000007788 liquid Substances 0.000 claims abstract description 22
239000000203 mixture Substances 0.000 claims description 47
238000009472 formulation Methods 0.000 claims description 42
PBRWGFLPYQYNGI-UHFFFAOYSA-N 2-[[2-[[3-(2-aminoethyl)-1h-indol-5-yl]oxy]acetyl]amino]-n-(2-amino-2-oxoethyl)-3-(4-hydroxyphenyl)propanamide Chemical compound C1=C2C(CCN)=CNC2=CC=C1OCC(=O)NC(C(=O)NCC(N)=O)CC1=CC=C(O)C=C1 PBRWGFLPYQYNGI-UHFFFAOYSA-N 0.000 claims description 40
APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 claims description 18
238000000034 method Methods 0.000 claims description 10
239000003755 preservative agent Substances 0.000 claims description 8
230000002335 preservative effect Effects 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 7
-1 alkali metal benzoate Chemical class 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 6
235000010234 sodium benzoate Nutrition 0.000 claims description 6
239000004299 sodium benzoate Substances 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 2
125000001931 aliphatic group Chemical group 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims description 2
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
150000004985 diamines Chemical class 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
150000007522 mineralic acids Chemical class 0.000 claims description 2
150000007524 organic acids Chemical class 0.000 claims description 2
235000005985 organic acids Nutrition 0.000 claims description 2
150000002989 phenols Chemical class 0.000 claims description 2
229920000768 polyamine Polymers 0.000 claims description 2
150000003141 primary amines Chemical group 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
239000000243 solution Substances 0.000 description 20
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
210000002966 serum Anatomy 0.000 description 11
230000000694 effects Effects 0.000 description 10
238000004128 high performance liquid chromatography Methods 0.000 description 10
238000007920 subcutaneous administration Methods 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
238000003556 assay Methods 0.000 description 9
229940100656 nasal solution Drugs 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000002835 absorbance Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
239000000047 product Substances 0.000 description 4
238000002798 spectrophotometry method Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
239000005711 Benzoic acid Substances 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000012669 liquid formulation Substances 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
150000005690 diesters Chemical class 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000005189 flocculation Methods 0.000 description 2
230000016615 flocculation Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
210000002850 nasal mucosa Anatomy 0.000 description 2
229960002446 octanoic acid Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
238000005191 phase separation Methods 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000006190 sub-lingual tablet Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
238000006136 alcoholysis reaction Methods 0.000 description 1
238000013103 analytical ultracentrifugation Methods 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002282 antimigraine agent Substances 0.000 description 1
229940125684 antimigraine agent Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
208000002399 aphthous stomatitis Diseases 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
210000005178 buccal mucosa Anatomy 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960003708 sumatriptan Drugs 0.000 description 1
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1
229960001360 zolmitriptan Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Otolaryngology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Pulmonology (AREA)
Physiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL12742398A 1998-01-15 1998-12-07 A medicinal preparation for giving and penetrating mucous membranes in the nose, mouth and throat IL127423A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9800574A FR2773489B1 (fr)	1998-01-15	1998-01-15	Nouvelle composition destinee a la voie oromuqueuse notamment pernasale

Publications (2)

Publication Number	Publication Date
IL127423A0 IL127423A0 (en)	1999-10-28
IL127423A true IL127423A (en)	2004-06-20

Family

ID=9521962

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12742398A IL127423A (en)	1998-01-15	1998-12-07	A medicinal preparation for giving and penetrating mucous membranes in the nose, mouth and throat

Country Status (12)

Country	Link
US (1)	US6326401B1 (is)
EP (1)	EP0938895A1 (is)
JP (1)	JPH11286440A (is)
KR (1)	KR19990067901A (is)
AU (1)	AU743492B2 (is)
CA (1)	CA2256793A1 (is)
FR (1)	FR2773489B1 (is)
IL (1)	IL127423A (is)
IS (1)	IS4942A (is)
NO (1)	NO990120L (is)
NZ (1)	NZ333656A (is)
ZA (1)	ZA9920B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IS4518A (is) *	1997-07-09	1999-01-10	Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group	Nýtt lyfjaform fyrir bóluefni
CN1361694A (zh) *	1999-07-16	2002-07-31	天藤制药株式会社	粘膜吸收甘草甜素制剂
EP1277479A3 (en) *	2001-06-18	2003-01-29	Dsm N.V.	Alkali or alkaline earth metal benzoate particles
US20050063940A1 (en) *	2002-02-25	2005-03-24	Sveinbjorn Gizurarson	Bioadhesive agent
US6855332B2 (en)	2002-07-03	2005-02-15	Lyfjathroun Hf.	Absorption promoting agent
FI20022007A0 (fi) *	2002-11-08	2002-11-08	Juvantia Pharma Ltd Oy	Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
KR100670921B1 (ko) *	2005-07-11	2007-01-19	주식회사마성상사	타크롤리무스 경구투여용 제제

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2042295A1 (fr) *	1990-05-15	1991-11-16	Jacques Chauveau	Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
IT1255895B (it) *	1992-10-20	1995-11-17	Laura Chiodini	Composizioni farmaceutiche contenenti una calcitonina

1998
- 1998-01-15 FR FR9800574A patent/FR2773489B1/fr not_active Expired - Fee Related
- 1998-12-07 IL IL12742398A patent/IL127423A/en not_active IP Right Cessation
- 1998-12-31 EP EP98430029A patent/EP0938895A1/fr not_active Withdrawn
1999
- 1999-01-04 ZA ZA9900020A patent/ZA9920B/xx unknown
- 1999-01-06 US US09/225,742 patent/US6326401B1/en not_active Expired - Fee Related
- 1999-01-07 NZ NZ333656A patent/NZ333656A/xx unknown
- 1999-01-08 JP JP11003065A patent/JPH11286440A/ja active Pending
- 1999-01-11 IS IS4942A patent/IS4942A/is unknown
- 1999-01-11 CA CA002256793A patent/CA2256793A1/fr not_active Abandoned
- 1999-01-12 AU AU11294/99A patent/AU743492B2/en not_active Ceased
- 1999-01-12 NO NO990120A patent/NO990120L/no not_active Application Discontinuation
- 1999-01-14 KR KR1019990000881A patent/KR19990067901A/ko not_active Withdrawn

Also Published As

Publication number	Publication date
IL127423A0 (en)	1999-10-28
NO990120D0 (no)	1999-01-12
KR19990067901A (ko)	1999-08-25
EP0938895A1 (fr)	1999-09-01
NZ333656A (en)	2000-05-26
AU743492B2 (en)	2002-01-24
AU1129499A (en)	1999-08-05
NO990120L (no)	1999-07-16
FR2773489B1 (fr)	2001-03-23
US6326401B1 (en)	2001-12-04
JPH11286440A (ja)	1999-10-19
FR2773489A1 (fr)	1999-07-16
CA2256793A1 (fr)	1999-07-15
ZA9920B (en)	1999-07-05
IS4942A (is)	1999-07-16

Legal Events

Date	Code	Title
2004-11-24	FF	Patent granted
2005-02-20	KB	Patent renewed
2010-04-08	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0524587B1 (en)	1995-11-29	Therapeutic compositions for intranasal administration which include ketorolac TM
US4788221A (en)	1988-11-29	Pharmaceutical compositions comprising calcitonin and an absorption-promoting substance
US4548922A (en)	1985-10-22	Drug administration
US6485706B1 (en)	2002-11-26	Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
JP3350061B2 (ja)	2002-11-25	エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物
WO1997006813A1 (en)	1997-02-27	Mucosal preparation containing physiologically active peptide
WO2002020037A1 (fr)	2002-03-14	Composition pharmaceutique a administration orale liberee au niveau colique
KR20020059583A (ko)	2002-07-13	경비 항경련성 조성물 및 제어 공정
HU209247B (en)	1994-04-28	Process for producing nasally administrable pharmaceutical dosage form
NO338665B1 (no)	2016-09-26	Doseringssystem med kontrollert frigivning for nasale anvendelser
US5407911A (en)	1995-04-18	Parathyroid hormone-containing emulsion for nasal administration
US4789660A (en)	1988-12-06	Insulin administration using methyl and propyl paraben
US6326401B1 (en)	2001-12-04	Formulation for the oromucosal, in particular pernasal, route
EP0140434B1 (en)	1993-08-04	Pharmaceutical composition with systemic anticholineesterasic, agonistic-cholinergic and antimuscarinic activity
CN102264346A (zh)	2011-11-30	用于通过颊透粘膜途径来施用降血脂药的制剂
CN121465997A (zh)	2026-02-06	一种齐考诺肽鼻脑递释制剂
HU226736B1 (en)	2009-08-28	Transmucosal formulations of levosimendan
US12042491B1 (en)	2024-07-23	Pharmaceutical formulations of quinolines
CN106309392A (zh)	2017-01-11	一种甲地高辛口腔快速吸收制剂及其制备方法
JP3498041B2 (ja)	2004-02-16	プラルモレリン含有点鼻用製剤
JP2973077B2 (ja)	1999-11-08	ビタミンｅ製剤組成物
JP2001505222A (ja)	2001-04-17	生物体にペプチド系医薬を導入するための局所用製剤
JPH07126159A (ja)	1995-05-16	乳剤性軟膏剤
KR20230035600A (ko)	2023-03-14	Ghrh 유사체의 저-용량 약제학적 조성물 및 이들의 용도
CN116327681A (zh)	2023-06-27	包含取代的咪唑并[1,2-α]吡啶-2-基胺盐酸盐水合物的凝胶制剂